首页 › 基金 › ACT Capital Partners, L.P. › CBIO

ACT Capital Partners, L.P. 对 CBIO 的持仓历史

CRESCENT BIOPHARMA INC. · 医疗保健

ACT Capital Partners, L.P. 在 Q3 2026 的 13F 申报中披露持有 CBIO(CRESCENT BIOPHARMA INC.)11,500 股,市值约 US$168K,约占其申报组合的 0.11%,在其申报持仓中市值排名第 49 位。 ACT Capital Partners, L.P. 于 Q3 2026 首次申报该持仓。

最新持仓 (Q3 2026)11.50K 股
申报持仓市值$167.78K
组合权重0.11%
首次申报Q3 2026
最近变动新进
更新于2026-11-07

最后更新: 2026-11-07 · 来源: SEC EDGAR Form 13F-HR

ACT Capital Partners, L.P. 对 CBIO 的持仓演变

ACT Capital Partners, L.P. 于 Q3 2026 首次披露 CBIO 持仓:11,500 股(约 US$168K)。

逐季持仓明细

季度股数金额变化
Q3 2026 11.50K $167.78K 新进

关于 CBIO 与 13F 数据

CBIO(CRESCENT BIOPHARMA INC.)属于医疗保健行业。我们追踪的基金中还有 72 只申报持有 CBIO,申报仓位最大的包括:BVF INC/IL (US$49.5M), Fairmount Funds Management LLC (US$49.5M), Venrock Adviser, LLC (US$38.4M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 CBIO 的基金

查看 CBIO 的全部基金持有人 →

常见问题

How long has ACT Capital Partners, L.P. held CBIO?

ACT Capital Partners, L.P. has disclosed CBIO holdings in 1 of the last 1 reported quarters, going back to Q3 2026.

What is ACT Capital Partners, L.P.'s current position in CBIO?

As of Q3 2026, ACT Capital Partners, L.P. holds 11.50K shares of CBIO (CRESCENT BIOPHARMA INC.), valued at $167.78K, representing 0.11% of its reported portfolio and ranking #49.

Has ACT Capital Partners, L.P. been buying or selling CBIO?

In the latest 13F filing (Q3 2026), ACT Capital Partners, L.P. newly opened its position in CBIO.

Which other funds hold CBIO?

Other major institutional holders of CBIO include BVF INC/IL, Fairmount Funds Management LLC, Venrock Adviser, LLC, among 72 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.